Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer - 12/04/19
Doi : 10.1016/j.jaad.2018.10.022
Emily Boozalis, BA a, Ami A. Shah, MD, MHS b, Fredrick Wigley, MD b, Sewon Kang, MD a, Shawn G. Kwatra, MD a, c, ⁎ 
a Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Scleroderma Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
c Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
∗Correspondence to: Shawn G. Kwatra, MD, Cancer Research Building II, Johns Hopkins University School of Medicine, Ste 206, 1550 Orleans St, Baltimore, MD 21231Cancer Research Building IIJohns Hopkins University School of MedicineSte 2061550 Orleans StBaltimoreMD21231
| Funding sources: None. |
|
| Conflicts of interest: Dr Kwatra is an advisory board member for Menlo and Trevi Therapeutics. All other authors have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 5
P. 1449-1451 - mai 2019 Retour au numéro
Article précédent
- What do patients undergoing Mohs micrographic surgery want? Results of a patient values survey based on the Outpatient and Ambulatory Surgery Consumer Assessments of Healthcare Providers and Systems
- Paul R. Massey, Ruibin Wang, Simi D. Cadmus, Katherine R. Sebastian, Matthew C. Fox
- A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor
- Christine Pao-Ling Lin, Samantha Gordon, Min Ji Her, David Rosmarin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?